Regression of hepatic, mesenteric and hilar melanoma metastases after DAB/IL2 administration. A. Patient P3 was scanned by combination PET/CT imaging 2 weeks prior to DAB/IL2 administration (pre-DAB/IL2) and after completing four 3-week cycles of DAB/IL2 (post-DAB/IL2). The brain, heart and bladder have normal accumulations of the PET tracer 18F-fluorodeoxyglucose but several areas of increased metabolism consistent with melanoma metastases resolved after DAB/IL2 administration. B. CT imaging of patient P5 revealed a large right hilar mass and a mesenteric mass that both decreased in size after DAB/IL2 administration.